Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study.
<h4>Background</h4>The Systolic Blood Pressure Intervention Trial (SPRINT) showed significant reductions in death and cardiovascular disease (CVD) risk with a systolic blood pressure (SBP) goal of <120 mm Hg compared with a SBP goal of <140 mm Hg. Our study aimed to assess the appl...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-03-01
|
| Series: | PLoS Medicine |
| Online Access: | https://doi.org/10.1371/journal.pmed.1003515 |
| _version_ | 1819259650851209216 |
|---|---|
| author | Chao Li Kangyu Chen Victoria Cornelius Ewan Tomeny Yang Wang Xiaowei Yang Xiaodan Yuan Rui Qin Dahai Yu Zhenqiang Wu Duolao Wang Tao Chen |
| author_facet | Chao Li Kangyu Chen Victoria Cornelius Ewan Tomeny Yang Wang Xiaowei Yang Xiaodan Yuan Rui Qin Dahai Yu Zhenqiang Wu Duolao Wang Tao Chen |
| author_sort | Chao Li |
| collection | DOAJ |
| description | <h4>Background</h4>The Systolic Blood Pressure Intervention Trial (SPRINT) showed significant reductions in death and cardiovascular disease (CVD) risk with a systolic blood pressure (SBP) goal of <120 mm Hg compared with a SBP goal of <140 mm Hg. Our study aimed to assess the applicability of SPRINT to Chinese adults. Additionally, we sought to predict the medical and economic implications of this intensive SBP treatment among those meeting SPRINT eligibility.<h4>Methods and findings</h4>We used nationally representative baseline data from the China Health and Retirement Longitudinal Study (CHARLS) (2011-2012) to estimate the prevalence and number of Chinese adults aged 45 years and older who meet SPRINT criteria. A validated microsimulation model was employed to project costs, clinical outcomes, and quality-adjusted life-years (QALYs) among SPRINT-eligible adults, under 2 alternative treatment strategies (SBP goal of <120 mm Hg [intensive treatment] and SBP goal of <140 mm Hg [standard treatment]). Overall, 22.2% met the SPRINT criteria, representing 116.2 (95% CI 107.5 to 124.8) million people in China. Of these, 66.4%, representing 77.2 (95% CI 69.3 to 85.0) million, were not being treated for hypertension, and 22.9%, representing 26.6 (95% CI 22.4 to 30.7) million, had a SBP between 130 and 139 mm Hg, yet were not taking antihypertensive medication. We estimated that over 5 years, compared to standard treatment, intensive treatment would reduce heart failure incidence by 0.84 (95% CI 0.42 to 1.25) million cases, reduce CVD deaths by 2.03 (95% CI 1.44 to 2.63) million cases, and save 3.84 (95% CI 1.53 to 6.34) million life-years. Estimated reductions of 0.069 (95% CI -0.28, 0.42) million myocardial infarction cases and 0.36 (95% CI -0.10, 0.82) million stroke cases were not statistically significant. Furthermore, over a lifetime, moving from standard to intensive treatment increased the mean QALYs from 9.51 to 9.87 (an increment of 0.38 [95% CI 0.13 to 0.71]), at a cost of Int$10,997 per QALY gained. Of all 1-way sensitivity analyses, high antihypertensive drug cost and lower treatment efficacy for CVD death resulted in the 2 most unfavorable results (Int$25,291 and Int$18,995 per QALY were gained, respectively). Simulation results indicated that intensive treatment could be cost-effective (82.8% probability of being below the willingness-to-pay threshold of Int$16,782 [1× GDP per capita in China in 2017]), with a lower probability in people with SBP 130-139 mm Hg (72.9%) but a higher probability among females (91.2%). Main limitations include lack of specific SPRINT eligibility information in the CHARLS survey, uncertainty about the implications of different blood pressure measurement techniques, the use of several sources of data with large reliance on findings from SPPRINT, limited information about the serious adverse event rate, and lack of information and evidence for medication effectiveness on renal disease.<h4>Conclusions</h4>Although adoption of the SPRINT treatment strategy would increase the number of Chinese adults requiring SBP treatment intensification, this approach has the potential to prevent CVD events, to produce gains in life-years, and to be cost-effective under common thresholds. |
| first_indexed | 2024-12-23T19:13:23Z |
| format | Article |
| id | doaj.art-81e62299569d43158d72b6fd481ccc82 |
| institution | Directory Open Access Journal |
| issn | 1549-1277 1549-1676 |
| language | English |
| last_indexed | 2024-12-23T19:13:23Z |
| publishDate | 2021-03-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Medicine |
| spelling | doaj.art-81e62299569d43158d72b6fd481ccc822022-12-21T17:34:23ZengPublic Library of Science (PLoS)PLoS Medicine1549-12771549-16762021-03-01183e100351510.1371/journal.pmed.1003515Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study.Chao LiKangyu ChenVictoria CorneliusEwan TomenyYang WangXiaowei YangXiaodan YuanRui QinDahai YuZhenqiang WuDuolao WangTao Chen<h4>Background</h4>The Systolic Blood Pressure Intervention Trial (SPRINT) showed significant reductions in death and cardiovascular disease (CVD) risk with a systolic blood pressure (SBP) goal of <120 mm Hg compared with a SBP goal of <140 mm Hg. Our study aimed to assess the applicability of SPRINT to Chinese adults. Additionally, we sought to predict the medical and economic implications of this intensive SBP treatment among those meeting SPRINT eligibility.<h4>Methods and findings</h4>We used nationally representative baseline data from the China Health and Retirement Longitudinal Study (CHARLS) (2011-2012) to estimate the prevalence and number of Chinese adults aged 45 years and older who meet SPRINT criteria. A validated microsimulation model was employed to project costs, clinical outcomes, and quality-adjusted life-years (QALYs) among SPRINT-eligible adults, under 2 alternative treatment strategies (SBP goal of <120 mm Hg [intensive treatment] and SBP goal of <140 mm Hg [standard treatment]). Overall, 22.2% met the SPRINT criteria, representing 116.2 (95% CI 107.5 to 124.8) million people in China. Of these, 66.4%, representing 77.2 (95% CI 69.3 to 85.0) million, were not being treated for hypertension, and 22.9%, representing 26.6 (95% CI 22.4 to 30.7) million, had a SBP between 130 and 139 mm Hg, yet were not taking antihypertensive medication. We estimated that over 5 years, compared to standard treatment, intensive treatment would reduce heart failure incidence by 0.84 (95% CI 0.42 to 1.25) million cases, reduce CVD deaths by 2.03 (95% CI 1.44 to 2.63) million cases, and save 3.84 (95% CI 1.53 to 6.34) million life-years. Estimated reductions of 0.069 (95% CI -0.28, 0.42) million myocardial infarction cases and 0.36 (95% CI -0.10, 0.82) million stroke cases were not statistically significant. Furthermore, over a lifetime, moving from standard to intensive treatment increased the mean QALYs from 9.51 to 9.87 (an increment of 0.38 [95% CI 0.13 to 0.71]), at a cost of Int$10,997 per QALY gained. Of all 1-way sensitivity analyses, high antihypertensive drug cost and lower treatment efficacy for CVD death resulted in the 2 most unfavorable results (Int$25,291 and Int$18,995 per QALY were gained, respectively). Simulation results indicated that intensive treatment could be cost-effective (82.8% probability of being below the willingness-to-pay threshold of Int$16,782 [1× GDP per capita in China in 2017]), with a lower probability in people with SBP 130-139 mm Hg (72.9%) but a higher probability among females (91.2%). Main limitations include lack of specific SPRINT eligibility information in the CHARLS survey, uncertainty about the implications of different blood pressure measurement techniques, the use of several sources of data with large reliance on findings from SPPRINT, limited information about the serious adverse event rate, and lack of information and evidence for medication effectiveness on renal disease.<h4>Conclusions</h4>Although adoption of the SPRINT treatment strategy would increase the number of Chinese adults requiring SBP treatment intensification, this approach has the potential to prevent CVD events, to produce gains in life-years, and to be cost-effective under common thresholds.https://doi.org/10.1371/journal.pmed.1003515 |
| spellingShingle | Chao Li Kangyu Chen Victoria Cornelius Ewan Tomeny Yang Wang Xiaowei Yang Xiaodan Yuan Rui Qin Dahai Yu Zhenqiang Wu Duolao Wang Tao Chen Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study. PLoS Medicine |
| title | Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study. |
| title_full | Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study. |
| title_fullStr | Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study. |
| title_full_unstemmed | Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study. |
| title_short | Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study. |
| title_sort | applicability and cost effectiveness of the systolic blood pressure intervention trial sprint in the chinese population a cost effectiveness modeling study |
| url | https://doi.org/10.1371/journal.pmed.1003515 |
| work_keys_str_mv | AT chaoli applicabilityandcosteffectivenessofthesystolicbloodpressureinterventiontrialsprintinthechinesepopulationacosteffectivenessmodelingstudy AT kangyuchen applicabilityandcosteffectivenessofthesystolicbloodpressureinterventiontrialsprintinthechinesepopulationacosteffectivenessmodelingstudy AT victoriacornelius applicabilityandcosteffectivenessofthesystolicbloodpressureinterventiontrialsprintinthechinesepopulationacosteffectivenessmodelingstudy AT ewantomeny applicabilityandcosteffectivenessofthesystolicbloodpressureinterventiontrialsprintinthechinesepopulationacosteffectivenessmodelingstudy AT yangwang applicabilityandcosteffectivenessofthesystolicbloodpressureinterventiontrialsprintinthechinesepopulationacosteffectivenessmodelingstudy AT xiaoweiyang applicabilityandcosteffectivenessofthesystolicbloodpressureinterventiontrialsprintinthechinesepopulationacosteffectivenessmodelingstudy AT xiaodanyuan applicabilityandcosteffectivenessofthesystolicbloodpressureinterventiontrialsprintinthechinesepopulationacosteffectivenessmodelingstudy AT ruiqin applicabilityandcosteffectivenessofthesystolicbloodpressureinterventiontrialsprintinthechinesepopulationacosteffectivenessmodelingstudy AT dahaiyu applicabilityandcosteffectivenessofthesystolicbloodpressureinterventiontrialsprintinthechinesepopulationacosteffectivenessmodelingstudy AT zhenqiangwu applicabilityandcosteffectivenessofthesystolicbloodpressureinterventiontrialsprintinthechinesepopulationacosteffectivenessmodelingstudy AT duolaowang applicabilityandcosteffectivenessofthesystolicbloodpressureinterventiontrialsprintinthechinesepopulationacosteffectivenessmodelingstudy AT taochen applicabilityandcosteffectivenessofthesystolicbloodpressureinterventiontrialsprintinthechinesepopulationacosteffectivenessmodelingstudy |